Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Gilead has a strong HIV franchise with flagship treatment Biktarvy driving the growth. The company’s efforts to develop innovative HIV treatments for prevention are impressive as well.

Gilead is a dominant player in the HIV market. The company’s flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has ...

Gilead’s blockbuster HIV treatment Biktarvy holds a top spot on the Medicaid spending list, coming in second to AbbVie’s Humira in 2022, Jefferies analysts noted. The company’s products have ...

The company’s success has been largely built on its HIV treatment portfolio, including the blockbuster drug Biktarvy. Gilead has demonstrated strong operational execution, effectively controlling ...